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INTRODUCTION
Allogeneic BMT is the treatment of choice for patients
of appropriate age with CML [1,2]. In the allogeneic trans-
plant setting, the possibility of residual disease in the
spleen after a preparative regimen of high-dose cyclophos-
phamide and total-body irradiation (TBI) has been report-
ed [3]. In an attempt to optimize tumor cytoreduction,
splenectomy or splenic irradiation has been done before
marrow transplantation [4–8]. Despite the theoretical
advantage of such an approach, the role of splenic irradia-
tion remains controversial.
The current study reports the results of 37 consecutive
patients with CML in chronic or accelerated phase treated
with splenic irradiation before allogeneic BMT at a single
institution. All patients received the same preparative regi-
men and prophylaxis for GVHD. The role of splenic irradi-
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ABSTRACT
Allogeneic bone marrow transplantation (BMT) has become the treatment of choice for patients of appropriate age
with chronic myeloid leukemia (CML). In an attempt to enhance tumor cytoreduction, splenic radiation therapy (RT)
has been done before the allogeneic transplant, but the role of splenic RT in this setting remains controversial. The
purpose of this study is to evaluate the role of splenic RT before allogeneic BMT in patients with CML. Thirty-seven
patients with chronic (n=33) or accelerated (n=4) phase CML underwent BMT from April 1990 to January 1998. All
patients received splenic RT consisting of 500 cGy in five daily fractions (n=36) or 250 cGy in five daily fractions
(n=1) completed within 10 days before BMT. The conditioning regimen included total-body irradiation and
cyclophosphamide; etoposide was added to the regimen of patients in the accelerated phase. Continuous-infusion
cyclosporine and pulse methotrexate were administered to all patients for prophylaxis of graft-vs.-host disease
(GVHD). All patients achieved hematologic and cytogenetic remission. At a median follow-up of 37 months, the free-
dom from progression (FFP) and overall survival (OS) were 90 and 82%, respectively. None of the patients in acceler-
ated phase have relapsed. Five patients have died of late transplant-related complications while in complete remis-
sion. Acute GVHD of grade ‡ II was observed in 20% (14% grade II, 6% grade III). Fifty-one percent of patients
developed limited chronic GVHD. The median posttransplant creatinine level was 1.2 mg/dL (range 0.6–4.2). Renal
dysfunction, manifested as a persistent elevation in serum creatinine level (>1.2 mg/dL), was observed in 40% of the
patients. Only 8.5% had a creatinine level >2.0 mg/dL, and no patient required dialysis as a result of renal dysfunc-
tion. Seven patients (18.9%) developed pulmonary complications, which included idiopathic interstitial pneumonitis
(two), biopsy-proven interstitial fibrosis (four), and alveolar hemorrhage (one). The low relapse rate observed in this
study may reflect the use of splenic RT as a part of the cytoreductive regimen before BMT. The fractionation sched-
ule of 500 cGy in five daily fractions was well tolerated and did not appear to increase the toxicity of the preparative
regimen. These favorable results indicate that splenic RT deserves further investigation and may be of benefit as a
part of the conditioning regimen for patients receiving allogeneic BMT for CML.
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ation in this setting is evaluated with particular attention to
long-term survival, leukemic relapse, and toxicity.
MATERIALS AND METHODS
Patients
The study population (Table 1) consisted of 37 patients
with chronic (n=33) or accelerated (n=4) phase CML who
underwent an allogeneic BMT at our institution from 1990
to 1997. The criteria used for chronic, accelerated, and blas-
tic phases of CML were those defined by the International
Bone Marrow Transplant Registry [9]. All patients received
non–T-depleted marrow from an HLA-identical matched
related or unrelated donor, a single antigen–mismatched rel-
ative, or a two antigen–mismatched relative. Patients in blast
phase were not included in this study. All patients had cyto-
genetic analysis to detect BCR/ABL rearrangements at 1
year after the transplant. Clinical relapse was defined as the
development of hematologic changes characteristic of CML
and always included cytogenetic relapse. Acute GVHD was
classified as grade I to IV, and chronic GVHD was classified
as limited or extensive according to standard criteria [10,11].
Preparative regimen
All patients received a preparative regimen consisting of
60 mg/kg cyclophosphamide administered intravenously on
2 consecutive days followed by TBI. Patients in accelerated
phase also received a single intravenous administration of 30
mg/kg etoposide. TBI was delivered with parallel opposed
lateral 24-MV photon beams using a previously described
technique [12]. A total dose of 1200 cGy was delivered at
200 cGy twice a day over 3 consecutive days at a dose rate of
<10 cGy/min. 
GVHD prophylaxis
All patients received cyclosporin and methotrexate for
acute GVHD prophylaxis as previously described [13]. With
day 0 being the day of allogeneic marrow infusion,
cyclosporin was administered as a 24-hour continuous intra-
venous infusion through an indwelling catheter beginning
on day –1 until day 50. Beginning at a dose of 2.5
mg/kg/day, cyclosporin was subsequently adjusted to main-
tain whole blood levels between 325 and 375 ng/mL or
between 450 and 520 ng/mL as determined by radioim-
munoassay or fluorescence polarization immunoassay,
respectively. On day 50, patients were switched to oral
cyclosporin at a dose of 5 mg/kg twice a day with the excep-
tion of those with active gastrointestinal disease or the
inability to tolerate oral medications. Methotrexate was
administered as a bolus intravenous infusion at a dose of 15
mg/m2 on day 1 and 10 mg/m2 on days 3 and 6. Methotrex-
ate dose was held for a total bilirubin level of >3.0 mg/dL.
Splenic irradiation
The technical details of splenic irradiation are summa-
rized in Table 2. All patients received this treatment 7–10
days before BMT. Radiation fields were designed by clinical
examination, anatomic landmarks, and fluoroscopy. Field
sizes were width 9.5–24 cm and length 11–28 cm. The size
of the radiation treatment fields was corrected for Cer-
robend blocking (equivalent squares). Patients were treated
using parallel opposed anteroposterior-posteroanterior por-
tals on a megavoltage linear accelerator with energies of 4 or
6 MV. Thirty-six of the 37 patients received 100 cGy per
fraction prescribed to midplane for five daily fractions. One
patient received 50 cGy per fraction for five daily fractions. 
Table 1. Characteristics of the 37 patients studied













Female to male 11 (30)
Female to female 7 (19)
Male to male 9 (24)
Male to female 10(27)
Type of match
Matched sibling 28 (76)
Matched unrelated donor 4 (11)
Single antigen–mismatched relative 4 (11)
Two antigen–mismatched relative 1 (2)







<0.80 (low risk) 15 (41)
>0.80 (intermediate and high risk) 22 (59)
Table 2. Splenic irradiation
No. patients (%)
Dose (cGy)
100 3 5 36 (97)
50 3 5 1 (3)





4 MV 30 (81)




*Dose from splenic radiation and TBI (patient received additional palliative
radiotherapy [100 cGy 3 2] 28 days before transplant).
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Fluorescent in situ hybridization
Cytogenetic remission status was determined using fluores-
cent in situ hybridization on peripheral blood or bone marrow
samples. The probe (LSI bcr/abl, Vysis) was prepared according
to the manufacturer’s instructions. After overnight hybridiza-
tion, slides were washed in 0.43 SSC at 72°C for 60 seconds
and placed in 13 phosphate-buffered Dextran (PBD) (Oncor)
for 15 seconds before being placed in the dark to air-dry. The
slides were then stained with 30 ng/mL 49,6-diamidino-2-
phenylindole (DAPI) and viewed under ultraviolet light with a
triple bandpass filter. Interphase nuclei (300–500) were scored
for each patient. Sensitivity and specificity of the probe were
found to be within the limits described by the manufacturer.
Two representative areas were photographed for each patient.
Statistical analysis
Variables including age, sex, donor-recipient sex combi-
nation, degree of match, time interval from diagnosis to
BMT, and size of the splenic irradiation field (equivalent
square) were evaluated for their impact on FFP, OS, devel-
opment of acute or chronic GVHD (or both), and trans-
plant-related morbidity. FFP and OS rates were determined
by the Kaplan-Meier method and compared by using the
log-rank test. Survival was calculated from the date of initia-
tion of induction chemotherapy to the date of death or most
recent follow-up. FFR was calculated from the date of docu-
mented remission to the date of relapse or most recent fol-
low-up. The Mann-Whitney U test and contingency tests
with two-way data analysis were used to determine the effect
of splenic radiation field size on engraftment time, renal
dysfunction, frequency of GVHD, and mortality rates dur-
ing the posttransplant follow-up period. Sokal’s score was
determined for each patient to assess the distribution of
prognostic subgroups as previously described [14].
RESULTS
Thirty-seven patients with CML in chronic (n=33) or
accelerated (n=4) phase received splenic irradiation before
BMT. Age at time of transplantation ranged from 22 to 59
years (median 39). Marrow transplantation was performed
A
B
Figure 1. FFP and OS
Freedom from progression (A) and overall survival (B) in patients with CML undergoing splenic irradiation before allogeneic bone marrow transplantation.
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from a human leukocyte antigen (HLA)-identical sibling
donor in 28 patients, a matched unrelated donor in three
patients, a single-antigen mismatched relative in five patients,
and a two-antigen mismatched relative in one patient.
Patients had an average spleen size of 7.6 cm before marrow
transplantation. Average time from diagnosis to transplanta-
tion was 304 days. Patient characteristics at diagnosis and at
time of transplantation are summarized in Table 1.
Survival and relapse
All patients achieved hematologic and cytogenetic remis-
sion. At a median follow-up of 37 months (range 1–105), the
FFP and OS for the entire study group were 90 and 82%,
respectively. The actuarial OS and FFP curves for the chronic
and accelerated phase patients are shown in Fig. 1. None of
the patients transplanted in the accelerated phase of disease
experienced relapse. In one patient in the chronic phase, dis-
ease recurred 56 months after transplantation. The patient
was alive at last follow-up (63 months). A total of five deaths
occurred, two in patients in the accelerated phase and three in
patients in the chronic phase. All deaths were associated with
late transplant-related complications. Two patients died of
extensive chronic GVHD involving the liver, one of veno-
occlusive disease, and two of pulmonary complications con-
sisting of interstitial pneumonitis or bronchiolitis obliterans
(or both). All five patients were in complete clinical and cyto-
genetic remission at the time of death. The mean Sokal’s
score in our patient group was >0.8 (0.85 ± 0.10, range
0.3–2.5). Fifteen patients (41%) were in the inter-
mediate/high-risk group. Overall survival at 5 years was 89%
in the low-risk group (score <0.80, n=22) compared with 80%
in the intermediate/high-risk group (score >0.80, n=15). The
difference in survival rates between the two risk groups was
not statistically significant (p = 0.27, log-rank test). 
Recovery of peripheral blood values
No engraftment failure was encountered in the study
group; however, one patient experienced persistent throm-
bocytopenia, with platelet counts remaining <50,000/mm3 at
a follow-up of 15 months. The median time to engraftment
of white blood cells (WBC) (absolute neutrophil count
[ANC] >500) was 22.1 ± 5.6 days. Patients irradiated with
relatively larger splenic field size (>14 equivalent square) had
a mean engraftment time of 24.2 days compared with 20.8
days observed in the group with a smaller field size, but this
was not statistically significant (p = 0.18, Mann-Whitney U
test). The degree of match (fully vs. partially matched recip-
ient transplant) in transplants from sibling donors did not
affect the engraftment time (22.0 ± 1.4 vs. 21.7 ± 3.8 days, p
= 0.83, Mann-Whitney U test).
GVHD
Grade ‡ II GVHD developed in 20% of the patients
(14% grade II and 6% grade III/IV). Fifty-one percent of
patients developed limited chronic GVHD that did not
affect performance status. Twenty-one percent developed
extensive chronic GVHD. 
Toxicity
Serum creatinine level was within normal limits (0.6–1.2
mg/dL) in all but one patient before transplant. The median
posttransplant serum creatinine value was 1.2 mg/dL (range
0.6–4.2). Renal dysfunction, manifested as a persistent eleva-
tion in serum creatinine level (>1.2 mg/dL), was observed in
40% of the patients. Only 8.5% had a serum creatinine
value >2.0 mg/dL, and no patient required dialysis because
of renal dysfunction.
Seven patients (18.9%) developed a pulmonary complica-
tion. These included two with idiopathic interstitial pneu-
monitis or bronchiolitis obliterans (or both), four with biopsy-
proven interstitial fibrosis, and one with alveolar hemorrhage. 
Two patients developed late gastrointestinal (GI) toxici-
ty. One consisted of an upper GI hemorrhage with docu-
mented esophageal and gastric ulcers on endoscopy 9
months after transplant. The second patient developed
reflux esophagitis associated with a hiatal hernia.
DISCUSSION
Progress has been made in the treatment of CML. Allo-
geneic BMT in the chronic phase has resulted in long-term
survival rates of 50–80% and leukemia-free survival rates of
30–70% [2,8,15–20]. Table 3 summarizes the results of
series published since 1992 [2,8,15–20]. The spleen is both a
site of bulk disease before BMT and a potential site of resid-
ual disease after BMT in patients with CML. The low
relapse rate of 10% and the high overall survival rate of
82% reported in our study suggests that splenic irradiation
before transplantation may be an important component of
the successful treatment of these patients.
The European Group for Blood and Bone Marrow
Transplantation conducted a prospective randomized study
of splenic irradiation before BMT for CML in chronic
phase. The first two analyses, at 5 months and 2 years,
respectively, failed to show a benefit in the patients receiving
splenic irradiation [6,7]; however, a recent update [8] has
revealed a trend for better survival in patients receiving
splenic irradiation. On subset analysis, patients with non–T-
depleted marrows and high basophil counts had a significant
reduction in relapse rate with splenic irradiation (11 vs. 32%
at 6 years, p = 0.05). In our study, none of the patients
received T cell–depleted marrow. Because of the low relapse
rate, an association between the basophil count and the
relapse rate could not be determined. 
A potentially important factor determining outcome
may relate to how splenic irradiation is delivered. We have
uniformly employed a treatment scheme using a relatively
low daily dose (100 cGy) given in five fractions. This is in
contrast to that used the European randomized trial [6–8],
in which participating centers were allowed to choose from
three different options of 10 Gy once a day, 5 Gy twice a
day, or 3.3 Gy three times a day. Additionally, in that trial,
no uniformity existed with respect to dose rate, field size, or
treatment energy. One postulated benefit of the fractiona-
tion scheme used in our study is the probability of maintain-
ing a functional spleen after splenic irradiation and TBI. 
Limited data exist on the effects of irradiation to the
spleen. The tolerance threshold of the spleen to irradiation
is not clearly defined. Postmortem spleens of patients treat-
ed with radiation for Hodgkin’s disease weighed signifi-
cantly less than did unirradiated controls (75 vs. 210 g, p <
0.0001) [21]. Histologic changes observed in irradiated
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spleens included atrophy of the red pulp, intimal thickening
of the vasculature, fibrosis, and loss of sinusoidal pattern.
Functional hyposplenism, determined by radionuclide scans
showing significant reduction in spleen size and increased
number of pitted erythrocytes in the peripheral smear, has
been reported after 4000 cGy splenic irradiation [22]. In the
European randomized trial [6–8], 52 of 115 patients ran-
domized to splenic RT received 1000 cGy in one fraction,
which, when combined with TBI, is expected to ablate
splenic function in most cases. In contrast, the dose scheme
in the current study, 100 cGy five times a day, results in an
estimated biologically equivalent dose to the spleen that is
three- to fourfold less. As a consequence, even when splenic
RT is combined with TBI, the probability of retaining nor-
mal splenic function is much higher.
We postulate that a functional spleen may play several
roles in the posttransplant period. Studies have shown an
increased risk of acute GVHD, a higher death rate from
GVHD, a high risk of fungal infections, and late gram-posi-
tive bacterial sepsis in patients undergoing splenectomy
before BMT [23–26]. The spleen, therefore, may contribute
to lessening the severity of these complications, which are
often the proximate cause of death in posttransplant
patients. Kiger and Lenfant [27] have demonstrated that
bovine spleens produce peptides that suppress lethal
GVHD, supporting the hypothesis. The spleen may also act
as a filter for the transfused marrow and selectively
sequester alloreactive T cells that recognize minor trans-
plantation antigens [28]. Splenic irradiation delivered in low
doses, as in our study, may effectively eradicate disease in
the spleen before BMT without impairing these desirable
splenic functions.
Irradiation of the spleen also may play a role in prevent-
ing progression to the blastic phase of disease. Extramedul-
lary localized myeloblastic transformation may occur in the
spleen [29,30]. Evidence also exists from cytologic, kinetic,
and cytogenetic studies that the spleen may be the initial site
of blast crisis in CML [31]. 
In addition to the uniformity of splenic radiotherapy
technique, all patients in our study received the same pre-
transplant conditioning regimen, method of GVHD pro-
phylaxis, and supportive care. This differs from the Euro-
pean randomized study [6–8] in that the aforementioned
variables were applied according to the local protocol of
each of the 30 participating centers. Furthermore, our study
reflects more “modern” supportive care compared with the
European study, which was conducted from 1986 to 1990.
Distribution of patients according to risk groups (Table 1)
and the similarity of overall survival among the low-risk and
intermediate/high-risk groups (89 vs. 80% at 5 years, p =
0.27) suggest that allogeneic BMT after splenic irradiation
was equally effective for both categories without significant
skewing toward the low-risk category in our patient group.
A major concern with splenic irradiation is the potential
morbidity associated with injury to adjacent organs. The
fractionation schedule used in our study did not appear to
be associated with increased systemic toxicity or transplant-
related mortality compared with intensified conditioning
alone. The late pulmonary and renal complications observed
are similar to those seen in TBI regimens without splenic
irradiation [32–44]. The probability of developing late-onset
renal dysfunction in survivors of BMT has been reported to
be 20% at 1 year and 23% at 18 months [33,34]. The pres-
ence of GVHD has been significantly correlated with renal
Table 3. Survival data for patients with CML undergoing allogeneic BMT
Study Year No. Patients Splenectomy/splenic RT (%) Median follow-up (years) LFS(%) OS (%)
Biggs et al. [16] 1992 NS 3
Chronic 62 58 58
Accelerated 26 41 41
Blastic 27 25 25 
Wagner et al. [17]* 1992 79 <1 4.5 NS 52
Italian Cooperative Study Group [18]* 1993 50 0 8 34 43
Goldman et al. [19]* 1993 6 3
Hydroxyurea 292 61 NS
Busulfan 158 45 NS
Horowitz et al. [2] 1996 NS 3
Chronic 1699 57 NS
Accelerated 939 41 NS
Blastic 147 18 NS
Clift et al. [1]* 1996 325 NS 5 NS 75
Gratwohl et al. [8]* 1996 6
Splenic RT 115 100 72 (89†) 62
No splenic RT 114 0 70 57
van Rhee et al. [20]* 1997 373 NS 8 47 54
Current study 1999 100 3
Chronic 33 89 90
Accelerated 4 100 38
LFS, leukemia-free survival; NS, not stated.
*All patients were in the chronic phase.
†Patients without T cell depletion and basophil count >3%.
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dysfunction, increasing this probability to 39% [36]. Pul-
monary complications are a major source of morbidity and
mortality after BMT for hematologic malignancies. Intersti-
tial pneumonitis has been reported to occur in 10–50% of
transplant recipients, with an associated mortality of
20–85% [37,38]. Seven patients (18.9%) in our series devel-
oped a pulmonary complication. Two of these led to respira-
tory failure and death (Table 4).
We recognize the limitations of this single-institution
study with a small patient cohort; however, the age distribu-
tion, phase of disease, degree of match, and pretransplant
variables are comparable to those of larger reported series.
Our data suggest that the low relapse rate obtained may
reflect the use of splenic irradiation before transplant for
patients with CML. Because of the strong dependence of
late tissue toxicity on dose per fraction, we recommend that
if splenic radiation is used, it is delivered in relatively low
doses per fraction to a modest total dose. The use of 100
cGy per fraction for five daily fractions was well tolerated
and did not appear to increase the toxicity of the preparative
regimen. Our favorable results support further investigation
of the use of splenic irradiation in a randomized trial as part
of the conditioning regimen for allogeneic BMT for
patients with CML in chronic or accelerated phase.
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